Back to Search
Start Over
One gene to rule them all…and in the darkness bind them
- Publication Year :
- 2018
- Publisher :
- Taylor & Francis, 2018.
-
Abstract
- Pharmaceutical inhibition of the Human Epidermal growth factor Receptor 2 (HER2) oncogene has dramatically improved outcomes in HER2-amplified breast cancers. However, monotherapy HER2 inhibitors are not effective. We have recently reported that a co-amplified microRNA within the HER2 amplicon, leads to activation of the oncogene Myeloid Cell Leukemia-1 (MCL-1), tempering cell death responses to HER2 inhibitors. Importantly, HER2 inhibitors are sensitized to cell death by the addition of pharmacological MCL-1 inhibitors, which are entering clinical trials.
- Subjects :
- 0301 basic medicine
Cancer Research
Programmed cell death
Myeloid
Oncogene
Cell
Biology
Amplicon
03 medical and health sciences
Author's Views
030104 developmental biology
medicine.anatomical_structure
Apoptosis
hemic and lymphatic diseases
microRNA
medicine
Cancer research
Molecular Medicine
skin and connective tissue diseases
Gene
neoplasms
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....cd97b2d0389ea1e05e550c029aa8857a